Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver

Annals of Surgical Oncology

Volumn 21, Issue 7, 2014, Pages 2420-2428

  Lau, Lawrence F ^a   Williams, David S ^a,b   Lee, Sze Ting ^a   Scott, Andrew M ^a   Christophi, Christopher ^a   Muralidharan, Vijayaragavan ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE PLUS OXALIPLATIN; CEDIRANIB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLATINUM COMPLEX; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GLYCOLYSIS; HUMAN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; METABOLISM; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; RADIOLOGICAL PARAMETERS; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE; COLORECTAL NEOPLASMS; DIAGNOSTIC USE; FOLLOW UP; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SECONDARY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; ROC CURVE; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84902152754     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3590-0     Document Type: Article

References (32)

1. Grundmann RT. Current state of surgical treatment of liver metastases from colorectal cancer. World J Gastrointest Surg. 2011;3:183-96.
2. Popescu I, Alexandrescu ST. Surgical options for initially unresectable colorectal liver metastases. HPB Surg. 2012; 2012:454026.
3. Doci R, Gennari L, Bignami P, et al. Morbidity and mortality after hepatic resection of metastases from colorectal cancer. Br J Surg. 1995;82:377-81.
4. Wiering B, Krabbe PFM, Jager GJ, et al. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases: a systematic review and meta-analysis. Cancer. 2005;104:2658-70.
5. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-18.
6. Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999;189:291-9.
7. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Assoc Française Chir. 1996;77:1254-62.
8. Rees M, Tekkis PP, Welsh FKS, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer a multifactorial model of 929 patients. Ann Surg. 2008;247:125-35.
9. Ayez N, Lalmahomed ZS, Van der Pool AEM, et al. Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol. 2011;18:2757-63.
10. Nordlinger B, Van Cusem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of the targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20(6):985-92.
11. 18F-FDG PET/CT in the assessment of colorectal liver metastases. J Nucl Med. 2012;53:1-7.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
13. Wahl RL, Jacene H, Kasamon Y, et al. Response criteria in solid tumors. J Nucl Med. 2009;50:1-50.
14. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299-304.
15. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14:700-8.
16. De Geus-Oei LF, Van Laarhoven HWM, Visser EP, et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol. 2008;19:348-52.
17. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography. J Gastrointest Surg. 2012;16:394-400.
18. Hendlisz A, Golfinopoulos V, Garcia C, et al. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol. 2011;23:1687-93.
19. Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283-301.
20. Weber WA. Assessing tumor response to therapy. J Nucl Med. 2009;50(Suppl 1):1S-10S.
21. Tan MCB, Linehan DC, Hawkins WG, et al. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg. 2007;11:1112-9.
22. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939-45.
23. Knowles B, Welsh FKS, Chandrakumaran K, et al. Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy. HPB (Oxford). 2012;14:298-309.
24. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012;53:709-15.
25. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-82.
26. max: a phantom study. Phys Med Biol. 2008;53:4213-30.
27. 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:27-38.
28. Zhang H, Wroblewski K, Liao S, et al. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol. 2012;20(1):32-4.
29. 18F-FDG PET scans. J Nucl Med. 2007;48:1449-58.
30. Morgan B, Thomas A, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of vascular endothelial growth factor receptor kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol. 2003;21:3955-64.
31. Anzidei M, Napoli A, Zaccagna F, et al. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging. J Comput Assist Tomogr. 2011;35(6):690-6.
32. Cai G, Xu Y, Zhu J, et al. Diffusion-weighted magnetic resonance imaging for predicting the response of rectal cancer to neoadjuvant concurrent chemoradiation. World J Gastroenterol. 2013;19(33):5520-7.